Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.20
Views: 145

Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA

Dr Anis Hamid speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the CHAARTED trial.

After an overview of the history of the trial, he explains how this study provided a more personalised direction based on the CHAARTED trial outcomes.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation